Rajan Sharma
Stock Analyst at Goldman Sachs
(2.28)
# 3,108
Out of 5,055 analysts
174
Total ratings
46%
Success rate
0.8%
Average return
Main Sectors:
Stocks Rated by Rajan Sharma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EPA: ABVX ABIVAX Société Anonyme | Reiterated: Buy | €132.00 → €131.00 | €77.40 | +69.25% | 2 | Oct 13, 2026 | |
| LON: GSK GSK plc | Reiterated: Hold | 1,890p → 1,860p | 1,760p | +5.71% | 32 | Oct 5, 2026 | |
| BIT: PHIL Philogen S.p.A. | Reiterated: Hold | €18.00 → €21.00 | €21.50 | -2.33% | 9 | Oct 2, 2026 | |
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 16,300p → 16,526p | 11,986p | +37.88% | 44 | Sep 29, 2026 | |
| ABVX ABIVAX Société Anonyme | Initiated Coverage: Buy | $155 | $86.22 | +79.77% | 1 | Sep 9, 2026 | |
| IMTX Immatics | Reiterated: Buy | $12 → $12 | $6.83 | +72.77% | 5 | Aug 18, 2026 | |
| AUTL Autolus Therapeutics | Rated: Buy | $5.7 → $5.8 | $1.62 | +258.02% | 6 | Aug 11, 2026 | |
| GMAB Genmab | Reiterated: Buy | $31 → $360 | $36.57 | +884.20% | 5 | Aug 7, 2026 | |
| IMCR Immunocore Holdings | Reiterated: Buy | $73 → $74 | $27.82 | +166.00% | 13 | Aug 6, 2026 | |
| VALN Valneva SE | Downgraded: Sell | $7.5 → $4.9 | $5.56 | -11.87% | 5 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $7.25 → $5.81 | $9.03 | -35.66% | 3 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Sell | €1.30 → €1.01 | €1.64 | -38.45% | 5 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $813 → $910 | $802.64 | +13.38% | 3 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.27 | - | 1 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.25 | - | 5 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 → $45 | $78.53 | n/a | 2 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €2.85 → €3.30 | €2.55 | n/a | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $109.62 | n/a | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | CHF 2.00 | CHF 4.19 | n/a | 8 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $121.08 | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $47 | $46.27 | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $33.35 | n/a | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €90.00 → €100.00 | €143.00 | n/a | 6 | Feb 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €44.00 | €52.95 | n/a | 7 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $20 | $13.50 | n/a | 2 | May 4, 2022 |
ABIVAX Société Anonyme
Oct 13, 2026
Reiterated: Buy
Price Target: €132.00 → €131.00
Current: €77.40
Upside: +69.25%
GSK plc
Oct 5, 2026
Reiterated: Hold
Price Target: 1,890p → 1,860p
Current: 1,760p
Upside: +5.71%
Philogen S.p.A.
Oct 2, 2026
Reiterated: Hold
Price Target: €18.00 → €21.00
Current: €21.50
Upside: -2.33%
AstraZeneca PLC
Sep 29, 2026
Reiterated: Buy
Price Target: 16,300p → 16,526p
Current: 11,986p
Upside: +37.88%
ABIVAX Société Anonyme
Sep 9, 2026
Initiated Coverage: Buy
Price Target: $155
Current: $86.22
Upside: +79.77%
Immatics
Aug 18, 2026
Reiterated: Buy
Price Target: $12 → $12
Current: $6.83
Upside: +72.77%
Autolus Therapeutics
Aug 11, 2026
Rated: Buy
Price Target: $5.7 → $5.8
Current: $1.62
Upside: +258.02%
Genmab
Aug 7, 2026
Reiterated: Buy
Price Target: $31 → $360
Current: $36.57
Upside: +884.20%
Immunocore Holdings
Aug 6, 2026
Reiterated: Buy
Price Target: $73 → $74
Current: $27.82
Upside: +166.00%
Valneva SE
Apr 22, 2026
Downgraded: Sell
Price Target: $7.5 → $4.9
Current: $5.56
Upside: -11.87%
Apr 9, 2026
Reiterated: Sell
Price Target: $7.25 → $5.81
Current: $9.03
Upside: -35.66%
Apr 9, 2026
Rated: Sell
Price Target: €1.30 → €1.01
Current: €1.64
Upside: -38.45%
Feb 26, 2026
Reiterated: Buy
Price Target: $813 → $910
Current: $802.64
Upside: +13.38%
Feb 17, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.27
Upside: -
Jan 9, 2026
Rated: Hold
Price Target: n/a
Current: $1.25
Upside: -
Jul 30, 2025
Reiterated: Buy
Price Target: $35 → $45
Current: $78.53
Upside: n/a
Mar 21, 2025
Reiterated: Hold
Price Target: €2.85 → €3.30
Current: €2.55
Upside: n/a
Oct 3, 2024
Reiterated: Hold
Price Target: n/a
Current: $109.62
Upside: n/a
Jul 30, 2024
Reiterated: Hold
Price Target: CHF 2.00
Current: CHF 4.19
Upside: n/a
May 30, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $121.08
Upside: n/a
May 30, 2024
Initiated Coverage: Hold
Price Target: $47
Current: $46.27
Upside: n/a
Dec 20, 2023
Reiterated: Buy
Price Target: n/a
Current: $33.35
Upside: n/a
Feb 13, 2023
Reiterated: Hold
Price Target: €90.00 → €100.00
Current: €143.00
Upside: n/a
May 16, 2022
Reiterated: Hold
Price Target: €44.00
Current: €52.95
Upside: n/a
May 4, 2022
Downgraded: Hold
Price Target: $40 → $20
Current: $13.50
Upside: n/a